Following on from information provided to NICE by the company in April 2020, the appraisal of Elotuzumab for untreated multiple myeloma [ID966] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 966

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
23 November 2022 Discontinued. Following on from information provided to NICE by the company in April 2020, the appraisal of Elotuzumab for untreated multiple myeloma [ID966] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
08 April 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of elotuzumab for untreated multiple myeloma [ID966] For information, the company have advised that the ELOQUENT-1 Study has failed to meet its primary endpoint and therefore they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
17 January 2020 Please note that following on from advice received from the company, the timelines for this appraisal are to be confirmed. A delay to the start of the appraisal is at the request of the company and we hope to have further information regarding the timelines for this appraisal in due course.
16 September 2019 Following on from advice received from the company this appraisal has now been scheduled back into the work programme. The appraisal is anticipated to begin during mid-March 2020 when we will write to you about how you can become involved. The deadline for submissions is expected in approximately late May 2020.
09 November 2018 Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations. Further information regarding the scheduling of this appraisal will be available in due course.
29 January 2018 In progress. In progress
07 December 2016 Suspended. Topic suspended.
22 July 2016 Referral

For further information on our processes and methods, please see our CHTE processes and methods manual